Beta-thalassemia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Beta-thalassemia}} Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. ==References==..." |
|||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Beta-thalassemia}} | {{Beta-thalassemia}} | ||
{{CMG}}; {{AE}} {{MHP}} | |||
==Overview== | |||
The long-term cost-effectiveness of therapy for beta-thalassemia major depends on factors such as access to healthcare resources, availability of blood products, affordability of [[chelation therapy]], and overall disease management. | |||
==Cost-effectiveness of therapy== | |||
The long-term cost-effectiveness of therapy for beta-thalassemia major depends on factors such as<ref name="pmid30700149">{{cite journal |vauthors=Coquerelle S, Ghardallou M, Rais S, Taupin P, Touzot F, Boquet L, Blanche S, Benaouadi S, Brice T, Tuchmann-Durand C, Ribeil JA, Magrin E, Lissillour E, Rochaix L, Cavazzana M, Durand-Zaleski I |title=Innovative Curative Treatment of Beta Thalassemia: Cost-Efficacy Analysis of Gene Therapy Versus Allogenic Hematopoietic Stem-Cell Transplantation |journal=Hum Gene Ther |volume=30 |issue=6 |pages=753–761 |date=June 2019 |pmid=30700149 |doi=10.1089/hum.2018.178 |url=}}</ref>: | |||
*Access to healthcare resources | |||
*Availability of blood products | |||
*Affordability of chelation therapy | |||
*Overall disease management | |||
==References== | ==References== | ||
Latest revision as of 05:58, 25 August 2023
|
Beta-thalassemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Beta-thalassemia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Beta-thalassemia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Beta-thalassemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]
Overview
The long-term cost-effectiveness of therapy for beta-thalassemia major depends on factors such as access to healthcare resources, availability of blood products, affordability of chelation therapy, and overall disease management.
Cost-effectiveness of therapy
The long-term cost-effectiveness of therapy for beta-thalassemia major depends on factors such as[1]:
- Access to healthcare resources
- Availability of blood products
- Affordability of chelation therapy
- Overall disease management
References
- ↑ Coquerelle S, Ghardallou M, Rais S, Taupin P, Touzot F, Boquet L, Blanche S, Benaouadi S, Brice T, Tuchmann-Durand C, Ribeil JA, Magrin E, Lissillour E, Rochaix L, Cavazzana M, Durand-Zaleski I (June 2019). "Innovative Curative Treatment of Beta Thalassemia: Cost-Efficacy Analysis of Gene Therapy Versus Allogenic Hematopoietic Stem-Cell Transplantation". Hum Gene Ther. 30 (6): 753–761. doi:10.1089/hum.2018.178. PMID 30700149.